Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review
Clinical and Experimental Dental Research · 2024
DOI: 10.1002/cre2.882 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Experimental Dental Research, 2024. Verfasst von Yeganeh Naderi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oral and Dental Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Carbamazepine, Oxcarbazepine, Botulinum Toxins, Type A. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objectives
This review aimed to compare the effectiveness of three treatments: BTX A, CBZ, and OXB, in managing trigeminal neuralgia (TN). Material and Methods We conducted a thorough search for research articles related to our issue using specific keywords on several databases, including Cochrane Central Register of Controlled Trials, Science Direct, Scopus, PubMed, Elsevier, Springer Journals, Ovid Medline, EBSCO, and Web of Science. Our focus was on publications from 1965 to 2023.
Results
We retrieved 46 articles from the search and reviewed them carefully. Out of these, we selected 29 articles that met the inclusion criteria. Among the selected articles, 11 investigated the effects of CBZ and OXB, while 18 explored the impact of BTX A on the improvement of TN symptoms. The response rate ranged between 56% and 90.5% for CBZ and between 90.9% and 94% for OXB. The response rate for BTX A ranged between 51.4% and 100%. All these three treatments had a remarkable effect on the improvement of TN. Importantly, findings highlighted that side effects of CBZ and OXB could lead to treatment discontinuation in some cases, whereas BTX A's side effects have been minimal and less frequent.
Conclusions
Consequently, BTX A emerges as a promising alternative for TN treatment. However, additional clinical trials are necessary to validate this finding, and further research is required to establish a standardized protocol for administering BTX A in TN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oral and Dental Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Research Center for Modeling in Health, Kerman University of Medical Sciences, Kerman, Iran.
- Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Science, Tehran, Iran.
- Department of Dental Medicine, Karolinska Institute, Scandinavian Center for Orofacial Neuroscience (SCON), Huddinge, Sweden.
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
ORCID-Profile: Mohammad Shabani
Förderung
- None
Zitieren
APA
Naderi, Y., Rad, M., Sadatmoosavi, A., Khaleghi, E., Khorrami, Z., Chamani, G., & Shabani, M. (2024). Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research. https://doi.org/10.1002/cre2.882
Vancouver
Naderi Y, Rad M, Sadatmoosavi A, Khaleghi E, Khorrami Z, Chamani G, et al. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research. 2024. doi:10.1002/cre2.882
BibTeX
@article{Naderi2024,
author = {Naderi, Yeganeh and Rad, Maryam and Sadatmoosavi, Ali and Khaleghi, Elham and Khorrami, Zahra and Chamani, Goli and Shabani, Mohammad},
title = {Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review},
journal = {Clinical and Experimental Dental Research},
year = {2024},
doi = {10.1002/cre2.882}
}
EUVIMED